Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab or Temozolomide with Chemotherapy for High-Risk Rhabdomyosarcoma
NCT01055314Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2010
- Primary completion
- Jun 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of cixutumumab, temozolomide in rhabdomyosarcoma (RMS), sponsored by National Cancer Institute. Started Jan 2010; status: completed.
02
Drugs
cixutumumabtemozolomide
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT01055314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01055314.